|
| | Publication Year | Title | Author(s) |
| 41 | 2021 | Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. | Dunn, Catherine; Hong, Wei; Gibbs, Peter; Ackland, Stephen; Sjoquist, Katrin; Tebbutt, Niall C ; Price, Timothy; Burge, Matthew |
| 42 | 1-Nov-2020 | Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. | Gulhati, Pat; Yin, Jun; Pederson, Levi; Schmoll, Hans-Joachim; Hoff, Paulo; Douillard, Jean-Yves; Hecht, J Randolph; Tournigand, Christophe; Tebbutt, Niall C ; Chibaudel, Benoist; Gramont, Aimery De; Shi, Qian; Overman, Michael James |
| 43 | 1-Sep-2020 | Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. | Klein, Oliver ; Kee, Damien ; Nagrial, Adnan; Markman, Ben; Underhill, Craig; Michael, Michael; Jackett, Louise A ; Lum, Caroline; Behren, Andreas; Palmer, Jodie ; Tebbutt, Niall C ; Carlino, Matteo S; Cebon, Jonathan S |
| 44 | 20-Apr-2020 | Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. | Roy, Amitesh C; Shapiro, Jeremy; Burge, Matt; Karapetis, Christos S; Pavlakis, Nick; Segelov, Eva; Chau, Ian; Lordick, Florian; Chen, Li-Tong; Barbour, Andrew; Tebbutt, Niall C ; Price, Tim |
| 45 | Apr-2020 | Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO Congress 2019. | Lau, David K ; Burge, Matthew; Roy, Amitesh; Chau, Ian; Haller, Daniel G; Shapiro, Jeremy D; Peeters, Marc; Pavlakis, Nick; Karapetis, Christos S; Tebbutt, Niall C ; Segelov, Eva; Price, Timothy J |
| 46 | 19-Mar-2020 | Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA. | Gulhati, Pat; Yin, Jun; Pederson, Levi; Schmoll, Hans-Joachim; Hoff, Paulo; Douillard, Jean-Yves; Hecht, J Randolph; Tournigand, Christophe; Tebbutt, Niall C ; Chibaudel, Benoist; De Gramont, Aimery; Shi, Qian; Overman, Michael James |
| 47 | Mar-2020 | Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. | Williams, David S ; Mouradov, Dmitri; Browne, Clare; Palmieri, Michelle; Elliott, Meg J; Nightingale, Rebecca; Fang, Catherine G; Li, Rita; Mariadason, John M ; Faragher, Ian; Jones, Ian T; Churilov, Leonid ; Tebbutt, Niall C ; Gibbs, Peter; Sieber, Oliver M |
| 48 | 2020 | The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. | Clarke, Stephen John; Burge, Matthew; Feeney, Kynan; Gibbs, Peter; Jones, Kristian; Marx, Gavin; Molloy, Mark P; Price, Timothy; Reece, William H H; Segelov, Eva; Tebbutt, Niall C |
Loading...
2
0
20
0
false